Biomarkers in prostate cancer - Current clinical utility and future perspectives

被引：127

作者：

Kretschmer, Alexander ^{[1
,2
,3
]}

Tilki, Derya ^{[4
,5
]}

机构：

[1] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada

[2] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada

[3] Ludwig Maximilians Univ Munchen, Dept Urol, Munich, Germany

[4] Univ Hosp Hamburg Eppendorf, Prostate Canc Ctr, Martini Klin, Hamburg, Germany

[5] Univ Hosp Hamburg Eppendorf, Dept Urol, Hamburg, Germany

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2017年 / 120卷

关键词：

Biomarker; Prostate cancer; Molecular marker; Genetic marker; Prognostic; Predictive; CYCLE PROGRESSION SCORE; ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; PATIENT-DERIVED XENOGRAFTS; NEEDLE-BIOPSY SPECIMENS; CIRCULATING TUMOR-CELLS; GENE-EXPRESSION ASSAY; GENOMIC CLASSIFIER; REPEAT BIOPSY; HEALTH INDEX;

D O I：

10.1016/j.critrevonc.2017.11.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Current tendencies in the treatment course of prostate cancer patients increase the need for reliable biomarkers that help in decision-making in a challenging clinical setting. Within the last decade, several novel biomarkers have been introduced. In the following comprehensive review article, we focus on diagnostic (PHI (R), 4K score, SelectMDx (R), ConfirmMDx (R), PCA3, MiPS, ExoDX (R) mpMRI) and prognostic (OncotypeDX GPS (R) Prolaris (R), ProMark (R), DNA-ploidy, Decipher (R)) biomarkers that are in widespread clinical use and are supported by evidence. Hereby, we focus on multiple clinical situations in which innovative biomarkers may guide decision-making in prostate cancer therapy. In addition, we describe novel liquid biopsy approaches (circulating tumor cells, cell-free DNA) that have been described as predictive biomarkers in metastatic castration-resistant prostate cancer and might support an individual patient-centred oncological approach in the nearer future.

引用

页码：180 / 193

页数：14

共 107 条

[31] Clinical Evaluation of the PCA3 Assay in Guiding Initial Biopsy Decisions [J].

de la Taille, Alexandre ;

Irani, Jacques ;

Graefen, Markus ;

Chun, Felix ;

de Reijke, Theo ;

Kil, Paul ;

Gontero, Paolo ;

Mottaz, Alain ;

Haese, Alexander .

JOURNAL OF UROLOGY, 2011, 185 (06) :2119-2125

[32] Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy [J].

Den, Robert B. ;

Feng, Felix Y. ;

Showalter, Timothy N. ;

Mishra, Mark V. ;

Trabulsi, Edouard J. ;

Lallas, Costas D. ;

Gomella, Leonard G. ;

Kelly, W. Kevin ;

Birbe, Ruth C. ;

Mccue, Peter A. ;

Ghadessi, Mercedeh ;

Yousefi, Kasra ;

Davicioni, Elai ;

Knudsen, Karen E. ;

Dicker, Adam P. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (05) :1038-1046

[33] Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model [J].

Dijkstra, Siebren ;

Govers, Tim M. ;

Hendriks, Rianne J. ;

Schalken, Jack A. ;

Van Criekinge, Wim ;

Van Neste, Leander ;

Grutters, Janneke P. C. ;

Sedelaar, John P. Michiel ;

van Oort, Inge M. .

BJU INTERNATIONAL, 2017, 120 (05) :659-665

[34] A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result [J].

Donovan, M. J. ;

Noerholm, M. ;

Bentink, S. ;

Belzer, S. ;

Skog, J. ;

O'Neill, V. ;

Cochran, J. S. ;

Brown, G. A. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (04) :370-375

[35] Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy [J].

Erho, Nicholas ;

Crisan, Anamaria ;

Vergara, Ismael A. ;

Mitra, Anirban P. ;

Ghadessi, Mercedeh ;

Buerki, Christine ;

Bergstralh, Eric J. ;

Kollmeyer, Thomas ;

Fink, Stephanie ;

Haddad, Zaid ;

Zimmermann, Benedikt ;

Sierocinski, Thomas ;

Ballman, Karla V. ;

Triche, Timothy J. ;

Black, Peter C. ;

Karnes, R. Jeffrey ;

Klee, George ;

Davicioni, Elai ;

Jenkins, Robert B. .

PLOS ONE, 2013, 8 (06)

[36] Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].

Ferlay, Jacques ;

Soerjomataram, Isabelle ;

Dikshit, Rajesh ;

Eser, Sultan ;

Mathers, Colin ;

Rebelo, Marise ;

Parkin, Donald Maxwell ;

Forman, David ;

Bray, Freddie .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386

[37] Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer [J].

Filella, Xavier ;

Foj, Laura ;

Maria Auge, Josep ;

Molina, Rafael ;

Alcover, Joan .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (09) :1347-1355

[38] uPM3, a new molecular urine test for the detection of prostate cancer [J].

Fradet, YF ;

Saad, F ;

Aprikian, A ;

Dessureault, J ;

Elhilali, M ;

Trudel, C ;

Måsse, B ;

Piché, L ;

Chypre, C .

UROLOGY, 2004, 64 (02) :311-315

[39] Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy [J].

Freedland, Stephen J. ;

Gerber, Leah ;

Reid, Julia ;

Welbourn, William ;

Tikishvili, Eliso ;

Park, Jimmy ;

Younus, Adib ;

Gutin, Alexander ;

Sangale, Zaina ;

Lanchbury, Jerry S. ;

Salama, Joseph K. ;

Stone, Steven .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 86 (05) :848-853

[40] Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature [J].

Futterer, Jurgen J. ;

Briganti, Alberto ;

De Visschere, Pieter ;

Emberton, Mark ;

Giannarini, Gianluca ;

Kirkham, Alex ;

Taneja, Samir S. ;

Thoeny, Harriet ;

Villeirs, Geert ;

Villers, Arnauld .

EUROPEAN UROLOGY, 2015, 68 (06) :1045-1053

← 1 2 3 4 5 6 7 8 9 10 →